现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • BMS-309403 sodium
BMS-309403 sodium的可视化放大

BMS-309403 sodium

A cell-permeable, potent, and selective inhibitor of FABP4

原价
¥600-1100
价格
480-880
BMS-309403 sodium的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajcx32446
  • CAS: 2802523-05-1
  • 别名:
  • 分子式: C31H25N2NaO3
  • 分子量: 496.53
  • 纯度: >98%
  • 溶解度: Water: 100 mg/mL (201.40 mM); DMSO: 50 mg/mL (100.70 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

Fatty acid binding protein 4 (FABP4) is a lipid transport protein that is also known as adipocyte FABP and aP2. In addition to adipocytes, it is also abundant in macrophages, along with FABP5, the epidermal FABP.1 BMS309403 is a cell-permeable, potent inhibitor of FABP4 that targets the fatty acid-binding pocket (Ki < 2 nM).2 It is less effective against FABP3 and FABP5 (Kis = 250 and 350 nM, respectively).2 BMS309403 is orally active, reducing atherosclerosis in mice lacking apoplipoprotein E.3,4 It also protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice.3,5 FABP4 dose-dependently suppresses the release of MCP-1 from macrophages.1,5


1.Lan, H., Cheng, C.C., Kowalski, T.J., et al.Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesityJ. Lipid Res.52(4)646-656(2011) 2.Sulsky, R., Magnin, D.R., Huang, Y., et al.Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP)Bioorg. Med. Chem. Lett.17(12)3511-3515(2007) 3.Furuhashi, M., Tuncman, G., G?rgün, C.Z., et al.Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2Nature447959-965(2007) 4.Lee, M.Y., Li, H., Xiao, Y., et al.Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cellsBr. J. Pharmacol.162(7)1564-1576(2011) 5.Suhre, K., R?misch-Margl, W., de Angelis, M.H., et al.Identification of a potential biomarker for FABP4 inhibition: The power of lipidomics in preclinical drug testingJ. Biomol. Screen.16(5)467-475(2011)

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服